# üî¨ Blinatumomab Path Analysis Report

*Generated: 2025-12-07 14:00:25*

## 1. Drug Profile

| Property | Value |
|----------|-------|
| **Drug ID** | DB09052 |
| **Drug Name** | Blinatumomab |
| **Type** | drug |

## 2. Path Statistics

| Metric | Value |
|--------|-------|
| **Total Paths** | 100 |
| **Unique Diseases** | 71 |
| **Mean Attention** | 0.6048 |
| **Std Attention** | 0.0595 |
| **Min Attention** | 0.4464 |
| **Max Attention** | 0.7293 |

### Paths by Hop Count

| Hops | Count |
|------|-------|
| 2 | 400 |
| 3 | 400 |
| 4 | 400 |
| 5 | 400 |

## 3. Path Type Summary

| Path Type | Count | Description |
|-----------|-------|-------------|
| Drug Similarity | 100 | Paths through similar drugs |
| Protein Target | 0 | Paths through protein targets |
| Pathway | 0 | Paths through biological pathways |
| Biological Process | 0 | Paths through biological processes |
| Other | 0 | Other connection types |

### Key Similar Drugs

| Similar Drug | Max Attention | # Diseases |
|--------------|---------------|------------|
| Mestranol | 0.8280 | 8 |
| Chlorotrianisene | 0.8013 | 54 |
| Ibrutinib | 0.7934 | 3 |
| Tibolone | 0.7864 | 2 |
| Pentoxifylline | 0.7760 | 2 |
| Dabigatran etexilate | 0.7480 | 1 |
| Diethylstilbestrol | 0.7434 | 30 |

## 4. Top 20 Paths (by Combined Score)

### Path #1: neurotic disorder

**Path:**
```
[Blinatumomab] --(0.828)--> [Mestranol] --(0.538)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6832 |
| Combined Score | 0.4831 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Mestranol, which is associated with neurotic disorder. This suggests shared therapeutic mechanisms.

---

### Path #2: hypertensive disorder

**Path:**
```
[Blinatumomab] --(0.828)--> [Mestranol] --(0.523)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6754 |
| Combined Score | 0.4775 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Mestranol, which is associated with hypertensive disorder. This suggests shared therapeutic mechanisms.

---

### Path #3: macroglobulinemia

**Path:**
```
[Blinatumomab] --(0.793)--> [Ibrutinib] --(0.551)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6724 |
| Combined Score | 0.4755 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Ibrutinib, which is associated with macroglobulinemia. This suggests shared therapeutic mechanisms.

---

### Path #4: inherited porphyria

**Path:**
```
[Blinatumomab] --(0.828)--> [Mestranol] --(0.516)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6721 |
| Combined Score | 0.4752 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Mestranol, which is associated with inherited porphyria. This suggests shared therapeutic mechanisms.

---

### Path #5: ovarian carcinosarcoma

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.540)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6708 |
| Combined Score | 0.4743 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with ovarian carcinosarcoma. This suggests shared therapeutic mechanisms.

---

### Path #6: postmenopausal osteoporosis

**Path:**
```
[Blinatumomab] --(0.786)--> [Tibolone] --(0.555)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6706 |
| Combined Score | 0.4742 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Tibolone, which is associated with postmenopausal osteoporosis. This suggests shared therapeutic mechanisms.

---

### Path #7: uterine corpus leiomyoma

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.538)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6697 |
| Combined Score | 0.4735 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with uterine corpus leiomyoma. This suggests shared therapeutic mechanisms.

---

### Path #8: maligant granulosa cell tumor of ovary

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.537)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6693 |
| Combined Score | 0.4733 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with maligant granulosa cell tumor of ovary. This suggests shared therapeutic mechanisms.

---

### Path #9: porphyrin metabolism disease

**Path:**
```
[Blinatumomab] --(0.828)--> [Mestranol] --(0.510)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6692 |
| Combined Score | 0.4732 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Mestranol, which is associated with porphyrin metabolism disease. This suggests shared therapeutic mechanisms.

---

### Path #10: cerebral infarction

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.537)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6691 |
| Combined Score | 0.4731 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with cerebral infarction. This suggests shared therapeutic mechanisms.

---

### Path #11: hypertension

**Path:**
```
[Blinatumomab] --(0.828)--> [Mestranol] --(0.509)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6686 |
| Combined Score | 0.4728 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Mestranol, which is associated with hypertension. This suggests shared therapeutic mechanisms.

---

### Path #12: intrinsic asthma

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.536)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6684 |
| Combined Score | 0.4727 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with intrinsic asthma. This suggests shared therapeutic mechanisms.

---

### Path #13: migraine with or without aura, susceptibility to

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.535)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6682 |
| Combined Score | 0.4725 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with migraine with or without aura, susceptibility to. This suggests shared therapeutic mechanisms.

---

### Path #14: endometrium neoplasm

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.535)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6683 |
| Combined Score | 0.4725 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with endometrium neoplasm. This suggests shared therapeutic mechanisms.

---

### Path #15: anxiety disorder

**Path:**
```
[Blinatumomab] --(0.828)--> [Mestranol] --(0.508)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6682 |
| Combined Score | 0.4725 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Mestranol, which is associated with anxiety disorder. This suggests shared therapeutic mechanisms.

---

### Path #16: dysthymic disorder

**Path:**
```
[Blinatumomab] --(0.828)--> [Mestranol] --(0.508)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6681 |
| Combined Score | 0.4724 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Mestranol, which is associated with dysthymic disorder. This suggests shared therapeutic mechanisms.

---

### Path #17: ovarian small cell carcinoma

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6678 |
| Combined Score | 0.4722 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with ovarian small cell carcinoma. This suggests shared therapeutic mechanisms.

---

### Path #18: dementia (disease)

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6678 |
| Combined Score | 0.4722 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with dementia (disease). This suggests shared therapeutic mechanisms.

---

### Path #19: obsolete susceptibility to ischemic stroke

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6679 |
| Combined Score | 0.4722 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with obsolete susceptibility to ischemic stroke. This suggests shared therapeutic mechanisms.

---

### Path #20: myxedema

**Path:**
```
[Blinatumomab] --(0.801)--> [Chlorotrianisene] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6675 |
| Combined Score | 0.4720 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Blinatumomab is similar to Chlorotrianisene, which is associated with myxedema. This suggests shared therapeutic mechanisms.

---

## 5. Interpretation Guidelines

### Attention Score Scale

| Score Range | Confidence | Interpretation |
|-------------|------------|----------------|
| ‚â• 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High | Strong biological relationship |
| 0.60 - 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê High | Good evidence for connection |
| 0.50 - 0.60 | ‚≠ê‚≠ê‚≠ê Medium | Moderate support |
| 0.40 - 0.50 | ‚≠ê‚≠ê Low | Weak connection |
| < 0.40 | ‚≠ê Very Low | Speculative |

### How to Use This Report

1. **Prioritize high-scoring paths**: Focus on paths with combined scores > 0.45
2. **Validate intermediate nodes**: Cross-reference proteins/drugs with literature
3. **Consider path length**: Shorter paths (2-3 hops) are generally more reliable
4. **Check for known associations**: Some paths may represent known indications

---

*Report generated by TxGNN Path Analysis Pipeline*